Facebook Pixel Can Med Tourism Industry Hit Goldmine With Robot-Assisted Surgery? | BioSpectrum Asia - Business - Bu hikayeyi Magzter.com'da okuyun

Denemek ALTIN - Özgür

Can Med Tourism Industry Hit Goldmine With Robot-Assisted Surgery?

BioSpectrum Asia

|

BioSpectrum Asia March 2023

The quality of Healthcare is projected to become enhanced in the future, aided by new innovations in technology.

Can Med Tourism Industry Hit Goldmine With Robot-Assisted Surgery?

Robot-assisted surgery (RAS) has seen significant advancement of late, bringing the promise of much better surgical and post surgical success rates. In the medical device industry, surgical robots are one of the fastest growing sectors. In addition to providing superior mobility, robotic surgery devices allow surgeons to reach confined spaces and provide extremely advanced imaging capabilities, with better dexterity. Yet, the robotic surgery industry is struggling to thrive in most developing countries. Let’s discover the reasons behind.

When compared with conventional laparoscopic and endoscopic techniques, robotic surgery allows intricate and advanced surgical procedures to be performed more precisely and with minimal skin incision.

To achieve maximum precision impact, robotassisted surgery platforms utilise electrosurgical hardware, instruments, artificial intelligence and data analytics. The robotic surgery minimises tissue damage, pain, and hospital readmissions as it is able to be implanted precisely during the surgery. In addition, with the 3-dimensional visualisation of image (rather than 2-dimensional vision in standard laparoscopy) surgical robotics further eliminates the risk of hand tremors. Advanced models offer voice-activated or manual master controls for demonstrating steady camera motion in addition to ergonomic design and training simulator. Despite the benefits of minimally invasive surgery (MIS), shorter hospital stays, and faster return to normal activities, only about 3 per cent of surgeries are performed robotically in the world.

Technological advancements have even enabled effective remote surgeries by demonstrating the tremendous potential of robotic aids and 5G technology. Surgeons and traumatologists are equitably empowered by the surgical robots technologies.

BioSpectrum Asia'den DAHA FAZLA HİKAYE

BioSpectrum Asia

BioSpectrum Asia

Alphamab Oncology appoints Fei Wang as Chief Financial Officer

Hong Kong-based Alphamab Oncology has announced the appointment of Fei Wang as the Chief Financial Officer (CFO).

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CarbGeM inks MoU with DSS Imagetech to expand AI business in Indian market

DSS Imagetech, a leading player in medical and research imaging equipment, has announced the signing of a Memorandum of Understanding (MoU) with Japan-based CarbGeM Inc., a developer of artificial intelligence (AI)-powered life science solutions to expand its AI business in the Indian market.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

PHCbi introduces LiCellGrow Cell Expansion System

PHC Corporation's Biomedical Division, a global provider of laboratory sample storage and cell cultivation solutions and subsidiary of Japan's PHC Holdings Corporation, has announced the launch of its new cell expansion system LiCellGrow for research use in Japan and other select countries worldwide.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

CitiusTech appoints Dhaval Shah as Chief Business Officer - MedTech & Life Sciences

CitiusTech, a leading provider of healthcare technology services driving digital and AI excellence in India, has appointed Dhaval Shah to Chief Business Officer - MedTech & Life Sciences.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Thermo Fisher expands immunodiagnostics operations with new distribution centre in Uppsala

Thermo Fisher Scientific Inc. has announced the opening of a new 8,000-square-meter distribution & labeling centre supporting its immunodiagnostics business in Uppsala.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Harbour BioMed appoints Dr Jenny Xie as Head of Global External Innovation

Harbour BioMed, a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, has announced the appointment of Dr Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Argo Biopharma ropes in Dr Gena Wang as CFO and CSO

China-based Argo Biopharmaceutical Co., a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, has announced the appointment of Dr Gena Wang as Chief Financial Officer (CFO) and Chief Strategy Officer (CSO), effective March 1, 2026.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

IISc launches "Moonshot" project on brain co-processors supported by Pratiksha Trust

The Indian Institute of Science (IISc), Bengaluru has launched an ambitious \"moonshot\" project to develop brain co-processors that combine neuromorphic hardware and artificial intelligence (AI) algorithms to enhance or restore brain function.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

Korea designs model for accurate and scalable drug-drug interaction prediction

A research team from the School of International Engineering and Science at Jeonbuk National University (JBNU), South Korea, has developed DDINet, a lightweight and scalable model, specifically designed to predict interactions for new, unseen drugs.

time to read

1 min

BioSpectrum Asia April 2027

BioSpectrum Asia

BioSpectrum Asia

Australia-Singapore study advocates role of intranasal vaccine booster against sarbecoviruses

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Monash University in Australia, have demonstrated that an intranasal vaccine booster may confer significantly stronger and broader immune responses, and provide robust neutralising antibody and resident T cell responses in the lung and nasal tissues, outperforming conventional mRNA booster vaccination.

time to read

1 min

BioSpectrum Asia April 2027

Translate

Share

-
+

Change font size